Current Report Filing (8-k)
February 14 2022 - 04:16PM
Edgar (US Regulatory)
0001500198 false 0001500198 2022-02-14
2022-02-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of
1934
Date
of Report (Date of Earliest Event Reported):
February 14, 2022
NeuroOne Medical Technologies Corporation
(Exact
name of registrant as specified in its charter)
|
Delaware |
|
000-54716 |
|
27-0863354 |
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File Number) |
|
(IRS
Employer
Identification No.) |
7599 Anagram Dr.,
Eden Prairie,
MN
55344
(Address
of principal executive offices and zip code)
952-426-1383
(Registrant’s
telephone number including area code)
(Registrant’s
former name or former address, if changed since last
report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
|
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
|
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
|
Common Stock, par value $0.001 per share |
|
NMTC |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
Growth Company
☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item
2.02 Results of Operations and Financial Condition.
On
February 14, 2022, NeuroOne Medical Technologies Corporation (the
“Company”) issued a press release announcing its financial results
for the first quarter ended December 31, 2021. A copy of this press
release is furnished herewith as Exhibit 99.1 to this Current
Report and is incorporated herein by reference.
In
accordance with General Instruction B.2. of Form 8-K, the
information in this Item 2.02, and Exhibit 99.1 hereto, shall not
be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise
subject to the liability of that section, nor shall it be deemed
incorporated by reference in any of the Company’s filings under the
Securities Act of 1933, as amended, or the Exchange Act, whether
made before or after the date hereof, regardless of any
incorporation language in such a filing, except as expressly set
forth by specific reference in such a filing.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as
amended, the Registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
NEUROONE
MEDICAL TECHNOLOGIES CORPORATION |
|
|
|
|
|
Dated:
February 14, 2022 |
By: |
/s/
David Rosa |
| |
|
David
Rosa |
| |
|
Chief
Executive Officer |
2
NeuroOne Medical Technol... (NASDAQ:NMTC)
Historical Stock Chart
From Jan 2023 to Feb 2023
NeuroOne Medical Technol... (NASDAQ:NMTC)
Historical Stock Chart
From Feb 2022 to Feb 2023
